Developer docs
API playgroundTry for free, no card

Search company profiles

Stemgent

Full company profile

uuid003iaez

Namestring
Stemgent
Legal namestring
Stemgent
Websiteurl
stemgent.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Stemgent is a sub-brand of REPROCELL (Tokyo Stock Exchange: 4978.T) positioned as "The Stem Cell Experts," providing reagents, gene editing services, and GMP-grade cell manufacturing for induced pluripotent stem cell (iPSC) research and cell therapy development. The platform is anchored on StemRNA™ footprint-free RNA reprogramming technology for generating iPSC lines, the StemEdit™ gene editing service line (including AI-designed CRISPR for hypoimmune iPSC engineering), and GMP iPSC and iMSC Master Cell Bank manufacturing spanning facilities in Japan, the United States, and Europe (via a Histocell partnership), with additional operations in the UK and India (Bioserve subsidiary).

The portfolio spans research-grade reagents and ready-to-use iPSC lines through clinical-grade services including custom reprogramming, donor recruitment, gene editing, GMP cell manufacturing, and iPSC-derived exosome production. Customer segments include cell therapy developers, academic stem cell researchers, diagnostic developers, preclinical drug developers, and clinical drug developers, served through direct sales offices in the Americas, EMEA, Japan, and India, supplemented by a global distributor network and an online product catalog.

Revenue mechanics are split between distributed catalog sales of reagents, cells, and 3D culture products (including distributed partner brands such as Qkine, KOKEN, and Alvetex) and higher-value enterprise contracts for custom reprogramming, StemEdit gene editing, GMP manufacturing, and central lab/clinical trial services. Pricing is not publicly disclosed and is handled via inquiry-based quotes. Stemgent-specific revenue is not separately reported and is consolidated within REPROCELL's financials.

Short descriptiontext

Stemgent is the stem cell sub-brand of REPROCELL, providing iPSC reprogramming reagents (StemRNA), gene editing services (StemEdit), and GMP-grade iPSC manufacturing for cell therapy developers, academic researchers, and pharma/biotech customers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBeltsville, United States
HQ citystring
Beltsville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stem cell reagents, iPSC reprogramming kits, gene editing services, GMP cell manufacturing, regenerative medicine tools
Industry1 code
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Stem cell reagents and iPSC services
Social media profiles3 records
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Stemgent provides stem cell research reagents, custom induced pluripotent stem cell (iPSC) reprogramming services, gene editing services (StemEdit), and GMP-grade iPSC manufacturing for researchers and cell therapy developers. Offerings span from catalog research products (RNA reprogramming kits, cytokines, growth factors) to clinical-grade Master Cell Bank production and iPSC-derived exosome manufacturing for therapeutic applications.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Stemgent is a sub-brand of REPROCELL positioned as "The Stem Cell Experts" within REPROCELL's portfolio of four brands (Bioserve, Stemgent, Alvetex, and Biopta). Stemgent offers an integrated platform for stem cell research and development, combining StemRNA technology (reprogramming kits and characterized iPSC lines) with StemEdit gene editing services and products. The offering spans research-use products (StemRNA 3rd Gen Reprogramming Kit, ready-to-use iPSCs) through clinical-grade services (GMP iPSC production, StemEdit Clinical Gene Editing). The portfolio provides end-to-end solutions from donor sourcing and footprint-free reprogramming to precise gene editing and GMP manufacturing, enabling researchers and cell therapy developers to generate reliable, publication-ready data and scalable therapies.

Product and service8 records
1StemRNA 3rd Gen Reprogramming Kit
CategoryStem cell reagents / reprogramming kits
Description

RNA-based reprogramming kit that enables generation of induced pluripotent stem cells (iPSCs) from somatic cells using StemRNA footprint-free technology, intended for stem cell researchers and cell therapy developers.

2StemRNA Human iPSCs
CategoryCell products / iPSC lines
Description

Ready-to-use research-grade induced pluripotent stem cell lines produced via StemRNA RNA-based reprogramming, providing characterized and quality-controlled pluripotent stem cells for research applications.

3StemEdit Gene Editing Services
CategoryGene editing services
Description

Custom gene editing services and products for stem cells, offering knockout, knock-in, and hypoimmune engineering capabilities for researchers and clinical-stage cell therapy developers.

4StemEdit Hypoimmune Cell Lines
CategoryGene-edited cell products
Description

Gene-edited iPSC lines featuring hypoimmune modifications such as B2M knockout, designed to reduce immune rejection for off-the-shelf cell therapy applications.

5GMP iPSC & iMSC MCB Manufacturing
CategoryGMP cell manufacturing services
Description

Clinical-grade GMP-compliant manufacturing service producing induced pluripotent stem cells (iPSCs) and induced mesenchymal stem cells (iMSCs) with Master Cell Bank (MCB) capabilities, for cell therapy developers requiring regulatory-aligned manufacturing.

6iPSC-Derived Exosome Production Service
CategoryCell-derived product services
Description

Custom production of exosomes derived from induced pluripotent stem cells (iPSCs) for therapeutic development and research applications.

7Stem Cell Reagent Product Catalog
CategoryStem cell research reagents
Description

A comprehensive catalog offering of stem cell research reagents — including RNA reprogramming kits, small molecules, growth factors, cytokines, antibodies, staining kits, culture media, cell substrates, cryopreservation media, dissociation solutions, and transfection reagents — sold to academic and industrial stem cell researchers.

8Stem Cell Product Catalog
CategoryStem cell product catalog
Description

Catalog offering of cell products supporting stem cell research and cell-based therapies, including iPSC-derived exosomes and related reagents.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Histocell serves as REPROCELL's GMP cell manufacturing partner for Europe, providing GMP-grade iPSC and MSC (mesenchymal stem cell) MCB (Master Cell Bank) manufacturing capabilities for the European market.

2Bioserve India
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Bioserve Biotechnologies (India) Private Ltd. operates as REPROCELL's Indian subsidiary, providing biospecimen services and supporting genomic services across the Indian market.

reprocell.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Global partner network for human tissue samples and biospecimen procurement, enabling access to specimens across multiple geographies for diagnostic and preclinical research.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Qkine provides growth factors and cytokines that are distributed through REPROCELL's product catalog as part of the stem cell reagent offerings.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

KOKEN's Atelocollagen (AteloCell) products for 3D cell culture are distributed through REPROCELL's product catalog.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Network of suppliers for human tissue specimens supporting preclinical drug testing and research, enabling access to fresh human tissues for drug discovery assays.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Leading specialty provider of stem cell reagents, culture media, and cell isolation products for research and clinical applications. Directly competes with Stemgent's stem cell reagent portfolio.

TypeEmerging player
Description

Clinical-stage company developing iPSC-derived allogeneic cell therapies with gene editing for hypoimmunity. Direct modality competitor and potential customer for Stemgent's hypoimmune iPSC engineering services.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing iPSC-derived off-the-shelf cell therapies. Represents both a potential customer for Stemgent's GMP services and a competing end-product developer in the same modality space.

TypeBroad incumbent
Description

Broad life science consumables and services company offering stem cell reagents, culture media, and cell therapy development services. Competes across Stemgent's reagent catalog and certain service offerings.

TypeDirect peer
Description

Global contract development and manufacturing organization (CDMO) offering cell therapy manufacturing services including iPSC and MSC production. Directly competes with Stemgent's GMP iPSC and MCB manufacturing capabilities.

TypeEmerging player
Description

Emerging iPSC manufacturing platform combining AI-driven automation with GMP-compliant iPSC production. Competes with Stemgent on next-generation iPSC manufacturing approaches.

TypeEmerging player
Description

iPSC technology platform offering iPSC line banking, gene editing, and cell therapy development services. Competes with Stemgent's stem cell services and iPSC banking offerings.

TypeDirect peer
Description

Major commercial provider of iPSC lines, differentiated cell types, and iPSC-derived products for research and clinical use. Directly competes with Stemgent's StemRNA iPSCs and iPSC-derived cell offerings.

TypeBroad incumbent
Description

Major life science reagents company providing growth factors, cytokines, antibodies, and stem cell research products. Competes with Stemgent's Stemfactor and reagent offerings.

10Corning Life Sciences
TypeBroad incumbent
Description

Major supplier of cell culture products including 3D cell culture systems and culture media. Overlaps with REPROCELL/Stemgent's Alvetex 3D cell culture and media products.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stemgent

Stem cell reagents and iPSC servicesstemgent.com

Stemgent is the stem cell sub-brand of REPROCELL, providing iPSC reprogramming reagents (StemRNA), gene editing services (StemEdit), and GMP-grade iPSC manufacturing for cell therapy developers, academic researchers, and pharma/biotech customers globally.

What Stemgent does

Stemgent is a sub-brand of REPROCELL (Tokyo Stock Exchange: 4978.T) positioned as "The Stem Cell Experts," providing reagents, gene editing services, and GMP-grade cell manufacturing for induced pluripotent stem cell (iPSC) research and cell therapy development. The platform is anchored on StemRNA™ footprint-free RNA reprogramming technology for generating iPSC lines, the StemEdit™ gene editing service line (including AI-designed CRISPR for hypoimmune iPSC engineering), and GMP iPSC and iMSC Master Cell Bank manufacturing spanning facilities in Japan, the United States, and Europe (via a Histocell partnership), with additional operations in the UK and India (Bioserve subsidiary).

The portfolio spans research-grade reagents and ready-to-use iPSC lines through clinical-grade services including custom reprogramming, donor recruitment, gene editing, GMP cell manufacturing, and iPSC-derived exosome production. Customer segments include cell therapy developers, academic stem cell researchers, diagnostic developers, preclinical drug developers, and clinical drug developers, served through direct sales offices in the Americas, EMEA, Japan, and India, supplemented by a global distributor network and an online product catalog.

Revenue mechanics are split between distributed catalog sales of reagents, cells, and 3D culture products (including distributed partner brands such as Qkine, KOKEN, and Alvetex) and higher-value enterprise contracts for custom reprogramming, StemEdit gene editing, GMP manufacturing, and central lab/clinical trial services. Pricing is not publicly disclosed and is handled via inquiry-based quotes. Stemgent-specific revenue is not separately reported and is consolidated within REPROCELL's financials.

Stemgent firmographics

Firmographics
Name
Stemgent
Legal name
Stemgent
Website
https://stemgent.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Stemgent is the stem cell sub-brand of REPROCELL, providing iPSC reprogramming reagents (StemRNA), gene editing services (StemEdit), and GMP-grade iPSC manufacturing for cell therapy developers, academic researchers, and pharma/biotech customers globally.
Ownership category
akta.pro rank

Stemgent industry classification

Industry
Product category
Stem cell reagents and iPSC services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Stem cell reagents
  • IPSC reprogramming kits
  • Gene editing services
  • GMP cell manufacturing
  • Regenerative medicine tools

Where Stemgent is headquartered

Location

Headquarters

HQ city
Beltsville
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Stemgent business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Distribution channels5 records

Marketing channels5 records

Stemgent product offering

Product offering

Core offering

Stemgent provides stem cell research reagents, custom induced pluripotent stem cell (iPSC) reprogramming services, gene editing services (StemEdit), and GMP-grade iPSC manufacturing for researchers and cell therapy developers. Offerings span from catalog research products (RNA reprogramming kits, cytokines, growth factors) to clinical-grade Master Cell Bank production and iPSC-derived exosome manufacturing for therapeutic applications.

Product overview

Stemgent is a sub-brand of REPROCELL positioned as "The Stem Cell Experts" within REPROCELL's portfolio of four brands (Bioserve, Stemgent, Alvetex, and Biopta). Stemgent offers an integrated platform for stem cell research and development, combining StemRNA technology (reprogramming kits and characterized iPSC lines) with StemEdit gene editing services and products. The offering spans research-use products (StemRNA 3rd Gen Reprogramming Kit, ready-to-use iPSCs) through clinical-grade services (GMP iPSC production, StemEdit Clinical Gene Editing). The portfolio provides end-to-end solutions from donor sourcing and footprint-free reprogramming to precise gene editing and GMP manufacturing, enabling researchers and cell therapy developers to generate reliable, publication-ready data and scalable therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • StemRNA 3rd Gen Reprogramming Kit RNA-based reprogramming kit that enables generation of induced pluripotent stem cells (iPSCs) from somatic cells using StemRNA footprint-free technology, intended for stem cell researchers and cell therapy developers.
  • StemRNA Human iPSCs Ready-to-use research-grade induced pluripotent stem cell lines produced via StemRNA RNA-based reprogramming, providing characterized and quality-controlled pluripotent stem cells for research applications.
  • StemEdit Gene Editing Services Custom gene editing services and products for stem cells, offering knockout, knock-in, and hypoimmune engineering capabilities for researchers and clinical-stage cell therapy developers.
  • StemEdit Hypoimmune Cell Lines Gene-edited iPSC lines featuring hypoimmune modifications such as B2M knockout, designed to reduce immune rejection for off-the-shelf cell therapy applications.
  • GMP iPSC & iMSC MCB Manufacturing Clinical-grade GMP-compliant manufacturing service producing induced pluripotent stem cells (iPSCs) and induced mesenchymal stem cells (iMSCs) with Master Cell Bank (MCB) capabilities, for cell therapy developers requiring regulatory-aligned manufacturing.
  • iPSC-Derived Exosome Production Service Custom production of exosomes derived from induced pluripotent stem cells (iPSCs) for therapeutic development and research applications.
  • Stem Cell Reagent Product Catalog A comprehensive catalog offering of stem cell research reagents — including RNA reprogramming kits, small molecules, growth factors, cytokines, antibodies, staining kits, culture media, cell substrates, cryopreservation media, dissociation solutions, and transfection reagents — sold to academic and industrial stem cell researchers.
  • Stem Cell Product Catalog Catalog offering of cell products supporting stem cell research and cell-based therapies, including iPSC-derived exosomes and related reagents.

Companies that use Stemgent

Customer profile

Segments5 records

Ideal customer profiles4 records

Stemgent technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Stemgent partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • HistocellcoreStrategic or Co-development PartnerHistocell serves as REPROCELL's GMP cell manufacturing partner for Europe, providing GMP-grade iPSC and MSC (mesenchymal stem cell) MCB (Master Cell Bank) manufacturing capabilities for the European market.
  • Bioserve IndiacoreStrategic or Co-development PartnerBioserve Biotechnologies (India) Private Ltd. operates as REPROCELL's Indian subsidiary, providing biospecimen services and supporting genomic services across the Indian market.
  • Bioserve Partner NetworkcoreStrategic or Co-development PartnerGlobal partner network for human tissue samples and biospecimen procurement, enabling access to specimens across multiple geographies for diagnostic and preclinical research.
  • QkineminorChannel Partner/ Reseller/ DistributorQkine provides growth factors and cytokines that are distributed through REPROCELL's product catalog as part of the stem cell reagent offerings.
  • KOKENminorChannel Partner/ Reseller/ DistributorKOKEN's Atelocollagen (AteloCell) products for 3D cell culture are distributed through REPROCELL's product catalog.
  • Human Tissue Supplier NetworkcoreStrategic or Co-development PartnerNetwork of suppliers for human tissue specimens supporting preclinical drug testing and research, enabling access to fresh human tissues for drug discovery assays.

Scale indicators2 records

Recent moves3 records

Expansion highlights6 records

Stemgent competitors and assessment

Company assessment

Direct peers

  • Stemcell Technologies: Leading specialty provider of stem cell reagents, culture media, and cell isolation products for research and clinical applications. Directly competes with Stemgent's stem cell reagent portfolio.
  • Lonza: Global contract development and manufacturing organization (CDMO) offering cell therapy manufacturing services including iPSC and MSC production. Directly competes with Stemgent's GMP iPSC and MCB manufacturing capabilities.
  • FUJIFILM Cellular Dynamics: Major commercial provider of iPSC lines, differentiated cell types, and iPSC-derived products for research and clinical use. Directly competes with Stemgent's StemRNA iPSCs and iPSC-derived cell offerings.

Emerging players

  • Century Therapeutics: Clinical-stage company developing iPSC-derived allogeneic cell therapies with gene editing for hypoimmunity. Direct modality competitor and potential customer for Stemgent's hypoimmune iPSC engineering services.
  • Fate Therapeutics: Clinical-stage biopharmaceutical company developing iPSC-derived off-the-shelf cell therapies. Represents both a potential customer for Stemgent's GMP services and a competing end-product developer in the same modality space.
  • Cellino Biotech: Emerging iPSC manufacturing platform combining AI-driven automation with GMP-compliant iPSC production. Competes with Stemgent on next-generation iPSC manufacturing approaches.
  • Pluristyx: iPSC technology platform offering iPSC line banking, gene editing, and cell therapy development services. Competes with Stemgent's stem cell services and iPSC banking offerings.

Broad incumbents

  • Thermo Fisher Scientific: Broad life science consumables and services company offering stem cell reagents, culture media, and cell therapy development services. Competes across Stemgent's reagent catalog and certain service offerings.
  • Bio-Techne: Major life science reagents company providing growth factors, cytokines, antibodies, and stem cell research products. Competes with Stemgent's Stemfactor and reagent offerings.
  • Corning Life Sciences: Major supplier of cell culture products including 3D cell culture systems and culture media. Overlaps with REPROCELL/Stemgent's Alvetex 3D cell culture and media products.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Stemgent social profiles

Digital presence

Stemgent financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stemgent leadership team

Management profile

Number of profiles

Profiles1 record

Stemgent funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stemgent M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stemgent

What does Stemgent do?

Stemgent provides stem cell research reagents, custom induced pluripotent stem cell (iPSC) reprogramming services, gene editing services (StemEdit), and GMP-grade iPSC manufacturing for researchers and cell therapy developers. Offerings span from catalog research products (RNA reprogramming kits, cytokines, growth factors) to clinical-grade Master Cell Bank production and iPSC-derived exosome manufacturing for therapeutic applications.

Is Stemgent a public or private company?

Stemgent is a private company. It is classified as corporate owned and is currently operating.

When was Stemgent founded?

Stemgent was founded in 2007. It employs 11 to 50 people.

Where is Stemgent based?

Stemgent is headquartered in Beltsville, United States, in the North America region.

Who are Stemgent's main competitors?

Direct peers on record are Stemcell Technologies, Lonza and FUJIFILM Cellular Dynamics. Emerging players are Century Therapeutics, Fate Therapeutics, Cellino Biotech and Pluristyx. Broad incumbents are Thermo Fisher Scientific, Bio-Techne and Corning Life Sciences.

Does Stemgent have an API?

No public API is recorded for Stemgent.

What industry is Stemgent in?

Stemgent's product category is Stem cell reagents and iPSC services. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals